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Summary 
 
The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, 
Alaska, maintains a statewide surveillance system for invasive diseases caused by Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and Groups A and B Streptococci.  
Laboratories throughout the state are requested to send to AIP any isolates of these organisms recovered 
from a blood culture, CSF, or other normally sterile site. Isolate identification is confirmed and, when 
appropriate, serotyped and tested for antimicrobial susceptibility.  The objectives of this system are to 
provide information on disease rates within the state, monitor the emergence of antimicrobial resistance, 
and to monitor the effectiveness of implemented vaccine programs, such as the 23-valent pneumococcal 
polysaccharide vaccine, the 7-valent pneumococcal conjugate vaccine and Haemophilus influenzae type b 
vaccines. 
 






In 2001 - 2002, the total number of cases of invasive disease caused by these organisms reported to AIP 
were 192 S. pneumoniae, 21 H. influenzae, 12 N. meningitidis, 70 Group A Strep and 43 Group B Strep.  
Alaska Native populations had higher rates of disease than non-Native populations in all invasive disease 
except those caused by Group B Strep.  Rates of invasive pneumococcal disease were highest in Norton 
Sound; H. influenzae rates were highest in YK Delta.  Rates for each organism by region are presented in 
the following tables. 
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Group A Strep 
n (rate*) 
Group B Strep 
n (rate*) 
Anchorage 61 (14.9) 7 (1.7) 4 (1.0) 19 (4.6) 19 (4.6) 
Arctic Slope 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Bristol Bay 0 (0) 0 (0) 0 (0) 1 (13.3) 0 (0) 
Interior 14 (14.5) 0 (0) 1 (1.0) 7 (7.2) 0 (0) 
Kotzebue 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Norton Sound 6 (60.0) 0 (0) 1 (10.0) 0 (0) 0 (0) 
Southeast 17 (23.5) 2 (2.8) 0 (0) 1 (1.4) 1 (1.4)  
YK Delta 5 (20.9) 1 (4.2) 0 (0) 1 (4.2) 0 (0) 
Total 103 (16.3) 10 (1.6) 6 (0.9) 29 (4.6) 20 (3.2) 
*Cases per 100,000 
 









Group A Strep 
n (rate*) 
Group B Strep 
n (rate*) 
Anchorage 59 (14.1) 9 (2.2) 4 (1.0) 28 (6.7) 17 (4.1) 
Arctic Slope 1 (16.0) 0 (0) 0 (0) 0 (0) 0 (0) 
Bristol Bay 1 (13.6) 0 (0) 0 (0) 1 (13.6) 0 (0) 
Interior 11 (11.2) 1 (1.0) 2 (2.0) 5 (5.1) 4 (4.1) 
Kotzebue 1 (12.5) 0 (0) 0 (0) 1 (12.5) 0 (0) 
Norton Sound 5 (49.9) 0 (0) 0 (0) 0 (0) 0 (0) 
Southeast 5 (6.9) 0 (0) 0 (0) 2 (2.8) 2 (2.8) 
YK Delta 6 (24.8) 1 (4.1) 0 (0) 4 (16.5) 0 (0) 
Total 89 (13.8) 11 (1.7) 6 (0.9) 41 (6.4) 23 (3.6) 




AIP conducts statewide surveillance of invasive Streptococcus pneumoniae, Haemophilus influenzae, 
Neisseria meningitidis, and Groups A and B Streptococcus.  This program is part of a passive, laboratory-
based surveillance system in which laboratories from all hospitals throughout the state are encouraged to 
participate.  The population included in the AIP surveillance is the State of Alaska, which totaled 633,630 
persons in 2001 and 643,786 persons in 2002 (Alaska Department of Labor & Workforce Development, 
http://almis.labor.state.ak.us).  Case detection occurs year-round as participating laboratories send 
isolates recovered from sterile sites to the AIP lab in Anchorage, accompanied by basic demographic and 
clinical information on the cases.  Materials and forms for isolate shipment and data collection are 
provided to each lab by AIP.  At year-end, AIP asks that each laboratory review their records and provide 
information on any cases that may have been overlooked.  In 2001 and 2002, 24 labs in Alaska 
participated in the invasive disease surveillance system, either by sending isolates to the AIP lab 
throughout the year, conducting year-end record reviews, or both.  
 
AIP defines a case of invasive Streptococcus pneumoniae, Haemophilus influenzae, Neisseria 
meningitidis, or Groups A and B Streptococcus as an isolate of the bacteria from a normally sterile site, 
including blood, cerebrospinal fluid, pleural fluid, peritoneal fluid or joint fluid that has been taken from a 
resident of Alaska.  In addition, for Group A Streptococcus, isolates are requested from deep tissue 
infections such as might be collected from surgical debridement of cases of necrotizing fasciitis. 
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A total of 92 pneumococcal isolates were received at AIP in 2001 and 76 pneumococcal isolates 
were received in 2002.  An additional 11 cases in 2001 and 13 cases in 2002 were detected 
through year-end follow up with participating labs throughout the state for a total of 103 cases of 
invasive pneumococcal disease in 2001 and 89 cases in 2002.  Overall invasive pneumococcal 
cases rates for 2001 and 2002 were 16.3 and 13.8 per 100,000 persons per year respectively.  
Alaska rates for 2001 and 2002 were slightly less than the Active Bacterial Core Surveillance 
(ABCs) 2001 national projected rate of 17.1/100,000 (Active Bacterial Core Surveillance (ABCs) 
Report Emerging Infections Program Network Streptococcus pneumoniae, 2001).  ABCs is a 




Invasive Streptococcus pneumoniae cases were identified in each month of 2001 and 2002.  The 
smallest number of cases was reported in April during both years. 
 
Figure 2:  Invasive Pneumococcal Disease, by 









































































In 2001 and 2002, the state population was comprised of 19% Alaska Natives (Alaska 
Department of Labor & Workforce Development: http://almis.labor.state.ak.us 11/30/2003; 
2001, Alaska Natives 121,857, non-Natives 511,773; 2002, Alaska Natives 124,803, non-Natives 
518,983).  The percentages of all reported S. pneumoniae cases that occurred in 2001 and 2002 
among Alaska Natives were 30% and 48%, respectively.  In 2001, a total of 31 cases occurred 
among Alaska Natives, resulting in an age-adjusted rate of 26.2/100,000 persons per year.  
Seventy-two cases occurred among the non-Native population for an age-adjusted rate of 
14/100,000 persons per year.  The age-adjusted rate ratio of S. pneumoniae disease for the 
Alaska Native population compared with the non-Native population in 2001 is 1.9.  In 2002, a 
total of 43 cases occurred among Alaska Natives, resulting in an age-adjusted rate of 36/100,000 
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persons per year.  Forty-six cases occurred among the non-Native population for an age-adjusted 
rate of 8.6/100,000 persons per year.  The age-adjusted rate ratio of pneumococcal disease for the 
Alaska Native population compared with the non-Native population in 2002 is 4.2. 
 





Rate* % Male 
Deaths 
n (%) 
2001 Alaska Native 31 (30) 26.2 42 4 (13) 
 Non-Native† 72 (70) 14 52 8 (11) 
 Total 103  49 12 (12) 
2002 Alaska Native 43 (48) 36 47 5 (12) 
 Non-Native† 46 (52) 8.6 46 6‡ (13) 
 Total 89  66 11 (12) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
†Includes 14 cases in 2001 and 8 cases in 2002 for which race was unknown 




The highest percentage of invasive pneumococcal disease cases occurred in the Anchorage area 
in 2001 and 2002, 59% (61 cases) and 66% (59 cases) respectively.  Rates of disease, however, 
were highest in Norton Sound both years; 64.4/100,000 persons per year in 2001 and 
53.5/100,000 persons per year in 2002. 
 
Figure 3:  Invasive Pneumococcal Disease, Cases 




























































































Cases occurred in all age groups in 2001 and 2002.  In 2001, the age of cases ranged from 0.2 
years to 100.6 years with a median of 40.5 years.  In 2002, cases ranged in age from 0.2 years to 
94.3 years with a median of 45.4 years.  Overall, the highest rates of disease occurred in children 
less than 2 years old and in adults greater than 65 years old during both 2001 and 2002. 
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Figure 4:  Invasive Pneumococcal Disease by Age 

























Figure 5:  Invasive Pneumococcal Disease, Cases 




















































Figure 6:  Invasive Pneumococcal Disease, Cases 





















































Surveillance of Invasive Bacterial Disease in Alaska, 2001-2002                                          9 
When stratified by age and race, the highest rates of disease in 2001 and 2002 occurred in Alaska 
Native children less than 2 years old; 93.6/100,000 persons per year in 2001 and 130.7/100,000 
persons per year in 2002.  High rates of invasive pneumococcal disease also occurred in Alaska 
Natives greater than 65 years old in 2001, 74.9/100,000 persons per year, however, rates of 
disease in this age category declined to 42.8/100,000 persons per year in 2002.  Overall during 
2001 and 2002, rates of disease were higher in the Alaska Native population in all age categories 




The primary clinical presentation was determined by a review of the discharge diagnoses 
indicated in each patient’s individual medical record associated with the illness resulting in the 
culture.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the 
pneumococcal infection was recorded as the primary clinical presentation.  Pneumonia was the 
most common primary clinical presentation in 2001 (63%) and 2002 (62%) followed by 
septicemia (15.5% in 2001 and 20% in 2002).  Six cases had a secondary pneumococcal-related 
diagnosis in 2001:  2 pneumonia and 1 each endocarditis, septic arthritis, cellulitis and 
unspecified other.  In 2002, nine cases had a secondary pneumococcal-related diagnosis; eight of 
these were pneumonia and one was septic arthritis. 
 
Figure 7:  Primary Clinical Presentations of 

















































































In 2001 and 2002, blood was the most common source of a positive culture which was used to 
identify 93% of the 103 cases in 2001 and 91% of the 89 cases in 2002.  Cerebrospinal fluid was 
the positive site for 4% of cases in 2001 and 6% of cases in 2002.  The remaining cases in 2001 
were identified through joint fluid, peritoneal fluid and other unidentified sterile site (1 case 
each).  In 2002, the remaining cases were identified through pleural fluid (4 cases) and one case 
through an unidentified sterile site. 
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Mortality 
 
In 2001, the overall case fatality ratio for S. pneumoniae in Alaska was 11.7% (12 deaths out of 
103 cases) and in 2002, it was 12.4% (11 deaths out of 89 cases).  In both years, the case fatality 
ratio for non-Natives was higher than Natives; 13.8% (8 deaths) in non-Natives compared to 
12.9% (4 deaths) in Natives in 2001 and 13% (6 deaths) in non-Natives compared to 11.6% (5 
deaths) in Natives in 2002.  Although the majority of deaths occurred in the 19-54 year old age 
category in both 2001 (7 deaths) and 2002 (5 deaths), the highest case fatality ratios occurred in 
the 65+ age category; 18.8% (3 deaths) in 2001 and 26.7% (4 deaths) in 2002. 
 
Figure 8:  Invasive Pneumococcal Deaths & Case 






















































Serotyping of invasive pneumococcal isolates is performed at AIP using internationally 
standardized methods.  Serotype identification is based on the organism’s polysaccharide capsule 
which is a principle virulence factor for pneumococci.  This information provides a way to 
subtype organisms and to determine if the infection was due to a type that could be prevented by 
use of one of the two available pneumococcal vaccine types.  Serotyping was performed on 91 of 
the 103 S. pneumoniae cases that occurred in Alaska in 2001 and on 76 of the 89 cases in 2002. 
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Table 4:  Invasive Pneumococcal Serotype Distribution by Race and Age Group – Alaska, 2001 
  Alaska Native Non-Native Unknown 
Serotype Total n (%) <2 2-18 19-64 65+ <2 2-18 19-64 65+ All Ages 
01 5 (5.4) - 3 2 - - - - - - 
03 4 (4.3) - - - - - 1 3 - - 
04 10 (10.9) - - 1 - - 2 3 2 2 
06A 3 (3.3) - - - - - - 1 1 1 
06B 7 (7.6) - - 1 - 3 - 2 1 - 
07F 1 (1.1) - - - - - - 1 - - 
08 3 (3.3) 1 - 1 - - - 1 - - 
09N 3 (3.3) - - 2 - - - 1 - - 
09V 7 (7.6) - - 2 1 - - 2 1 1 
11A 4 (4.3) - - 1 - - - 2 1 - 
12F 6 (6.5) - - 1 - - - 5 - - 
14 16 (17.4) 1 - 1 - 1 3 4 1 5 
15A 1 (1.1) - - 1 - - - - - - 
17F 1 (1.1) - - - 1 - - - - - 
18C 2 (2.2) - - - - - - - 1 1 
19A 2 (2.2) - - - - 1 1 - - - 
19F 2 (2.2) 1 - - - 1 - - - - 
20 1 (1.1) - - - - 1 - - - - 
22F 2 (2.2) - - - 1 - - 1 - - 
23F 4 (4.3) - - - 1 - - - 1 2 
31 1 (1.1) - - - - - - 1 - - 
33F 3 (3.3) 1 - 1 - 1 - - - - 
34 1 (1.1) - - - - - - 1 - - 
NT* 2 (2.2) - - 1 - - - 1 - - 
Total 91 4 3 15 4 8 7 29 9 12 
*Non-typable 
 
Table 5:  Invasive Pneumococcal Serotype Distribution by Race and Age Group – Alaska, 2002 
  Alaska Native Non-Native Unknown 
Serotype Total n (%) <2 2-18 19-64 65+ <2 2-18 19-64 65+ All Ages 
03 4 (5.3) - 1 1 1 - - 1 - - 
04 12 (15.8) - - 4 1 - - 5 1 1 
05/10F 1 (1.3) - - 1 - - - - - - 
06A 3 (3.9) 1 - 1 - - - - - 1 
06B 3 (3.9) - 1 - - - - - 2 - 
07F 6 (7.9) - - 5 - - - 1 - - 
08 5 (6.6) - - 2 - - - 1 - 2 
09N 7 (9.2) - - 2 - - - 1 3 1 
10A 2 (2.6) - - - - - 1 1 - - 
12F 3 (3.9) - - 1 - 1 - - - 1 
14 5 (6.6) 1 - 2 - - - 1 1 - 
15B 1 (1.3) - - - - - 1 - - - 
15C 2 (2.6) 1 - - - - 1 - - - 
16F 4 (5.3) - - 2 - - 1 - 1 - 
19A 3 (3.9) - 1 1 - 1 - - - - 
19F 2 (2.6) - - 2 - - - - - - 
22A 3 (3.9) 1 - 1 - - - 1 - - 
22F 4 (5.3) 1 - 1 - 1 1 - - - 
23F 1 (1.3) - - - - - - 1 - - 
33F 2 (2.6) - - - 1 - - - 1 - 
38 3 (3.9) 2 - - - 1 - - - - 
Total 76 7 3 26 3 4 5 13 9 6 
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01 - - - - - - - - - - - - - - 5 - 
03 2 1 - - - 1 - 1 - 1 - - 2 - - - 
04 7 7 - - - - - - - - 2 - 1 5 - - 
05/10F - 1 - - - - - - - - - - - - - - 
06A 3 2 - - - 1 - - - - - - - - - - 
06B 4 3 - - - - - - - - 1 - 2 - - - 
07F 1 2 - - - - - - - - - - - 1 - 3 
08 3 4 - 1 - - - - - - - - - - - - 
09N 3 6 - - - - - - - - - - - 1 - - 
09V 4 - - - - - - - - - 2 - 1 - - - 
10A - 2 - - - - - - - - - - - - - - 
11A 3 - - - - - - - - - - - 1 - - - 
12F 1 2 - - - - - - - - 5 1 - - - - 
14 9 4 - - 1 - - - - - 3 1 3 - - - 
15A - - - - - - - - - - 1 - - - - - 
15B - 1 - - - - - - - - - - - - - - 
15C - 1 - - - - - - - - - - - - - 1 
16F - 3 - - - - - - - - - - - 1 - - 
17F - - - - - - - - - - - - - - 1 - 
18C 1 - - - - - - - - - - - 1 - - - 
19A 2 1 - - - - - - - - - - - 1 - 1 
19F 1 1 - - - - - - - - 1 - - 1 - - 
20 - - - - - - - - - - - - 1 - - - 
22A - 1 - - - 2 - - - - - - - - - - 
22F - 3 - - 1 1 - - - - 1 - - - - - 
23F 2 1 - - - - - - - - 1 - 1 - - - 
31 1 - - - - - - - - - - - - - - - 
33F 2 2 - - 1 - - - - - - - - - - - 
34 1 - - - - - - - - - - - - - - - 
38 - 1 - - - 1 - - - - - - - 1 - - 
NT* 1 - - - - - - - - - - - 1 - - - 
*Non-typable 
 
In 2001, the most common serotypes were 14 (16 isolates, 17.4%) and 4 (10 isolates, 10.9%).  
The serotype 14 cases were distributed throughout the state, 9 in Anchorage, 3 each in the 
Southeast and Interior and one in the YK Delta.  Serotype 4 cases occurred in Anchorage (7 
cases), the Interior (5 cases) and Southeast (2 cases).  In 2002, the most common serotypes were 
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4 (12 isolates, 15.8%) and 9N (7 cases, 9.2%).  Both serotype 4 and serotype 9N cases occurred 
in Anchorage (7 cases serotype 4, 6 cases serotype 9N) and the Interior (5 cases serotype 4, 1 




Two vaccine types are licensed for prevention of pneumococcal disease.  In 2001, the 
pneumococcal conjugate vaccine (PCV7) was included in the Alaska childhood vaccination 
schedule.  This vaccine provides protection against the 7 most common pneumococcal serotypes 
causing invasive disease among children (types 4, 6B, 9V, 14, 18C, 19F, 23F).  The table below 
shows the proportion of invasive infections from 2001 and 2002 that were due to serotypes found 
in the PCV7 vaccine. 
 
Table 7:  Proportion of Invasive Isolates Contained in the PCV7 Vaccine by Age Group 
and Race – Alaska, 2001-2002 
Age 
(yrs) 
Alaska Native (%) Non-Native (%) Total (%) 
2001 2002 2001 2002 2001 2002 
<2 2 (40%) of 5 1 (14%) of 7 5 (63%) of 8 0 (0%) of 4 10 (59%) of 17 
1 (8%) of 
13 
2-4 0 (0%) of 0 0 (0%) of 2 1 (33%) of 3 0 (%) of 2 4 (67%) of 6 0 (0%) of 4 
5+ 
6 (27%) of 
22 
10 (33%) of 
30 
19 (45%) of 
42 
11 (44%) 
of  25 




8 (31%) of 
27 
11 (28%) of 
39 








The 23-valent polysaccharide vaccine (Ps23V) is recommended in Alaska for all persons 55 
years and older, and for persons over age 2 who are at higher risk for pneumococcal disease.  
Revaccination is recommended after 6 years.  In 2001 and 2002, for persons 55 years and older, 
18 (86%) of 21 and 22 (88%) of 25 cases serotyped, respectively, were potentially vaccine 




In 2001, pneumococcal vaccine status was known for 59 (57%) of the 103 cases; 21 cases (20%) 
did receive a pneumococcal vaccine prior to illness and 38 cases (37%) had no record of a 
pneumococcal vaccine.  Pneumococcal vaccine status in 2002 was known for 57 (64%) of the 89 
cases; 31 cases (35%) did receive a pneumococcal vaccine prior to illness. Twenty-six (29%) had 
no record of a pneumococcal vaccine. 
 
A PCV7 vaccine failure is defined as invasive pneumococcal disease caused by a serotype 
contained in the PCV7 vaccine in an individual who has had at least two doses of vaccine.  There 
were no vaccine failures in 2001 or 2002.  
 
Two of the 12 deaths in 2001 and 5 of the 11 deaths in 2002 from invasive S. pneumoniae were 
due to serotypes found in the PCV7 vaccine.  None of these deaths, however, occurred in persons 
in the age group for which vaccine is recommended (< 2 years).  Six of the 12 fatal cases in 2001 
(50%) and 8 of 11 in 2002 (73%) were due to serotypes contained within the 23-valent 
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polysaccharide vaccine.  Three cases in each year occurred in persons 55 years or older which is 
the age group eligible for this vaccine.  Vaccine status was known for 8 of the 12 deaths in 2001 
and 5 of the 11 deaths in 2002.  It is unknown if these individuals received the 7-valent or 23-
valent vaccine.  
 
Table 8:  Invasive Pneumococcal Disease, Serotypes of Fatal Cases – Alaska, 2001-2002 
 2001 2002 
Serotype Deaths (%) Serotype Frequency Deaths (%) Serotype Frequency 
03† 1 (25%) 4 0 (0%) 0 
04*† 1 (10%) 10 4 (33%) 12 
6A 1 (33%) 3 0 (0%) 0 
07F† 0 (0%) 0 1 (17%) 6 
09N† 1 (33%) 3 0 (0%) 0 
09V*† 1 (14%) 7 0 (0%) 0 
10A† 0 (0%) 0 1 (50%) 2 
16F 0 (0%) 0 1 (25%) 4 
17F† 1 (100%) 1 0 (0%) 0 
19F*† 0 (0%) 0 1 (50%) 2 
22F† 1 (50%) 2 0 (0%) 0 
31 1 (100%) 1 0 (0%) 0 
33F† 0 (0%) 0 1 (50%) 2 
NT 2 (100%) 2 0 (0%) 0 
*Serotypes contained in the PCV7 vaccine 
†Serotypes contained in the 23-valent polysaccharide vaccine 
 
Overall, 50% of all pneumococcal-related mortality in 2001 and 73% in 2002 was potentially 
preventable with the use of the 23-valent polysaccharide vaccine in persons over 2 years old. 
 
Table 9:  Potentially Vaccine Preventable Invasive Pneumococcal Deaths – Alaska, 2001 
 < 2 years 2-4 5-18 19-54 55-64 65+ Total 
PCV7 0 0 0 1 (14%) 1 (100%) 0 2 (17%) 
Ps23V 0 1 (100%) 0 2 (29%) 1 (100%) 2 (67%) 6 (50%) 
Total 0 1 0 7 1 3 12 
 
Table 10:  Potentially Vaccine Preventable Invasive Pneumococcal Deaths – Alaska, 2002 
 < 2 years 2-4 5-18 19-54 55-64 65+ Total 
PCV7 0 0 0 3 (60%) 1 (100%) 1 (25%) 5 (45%) 
Ps23V 0 0 1 (100%) 4 (80%) 1 (100%) 2 (50%) 8 (73%) 
Total 0 0 1 5 1 4 11 
 
Associated Medical Conditions 
 
The presence of one or more associated medical conditions was reported in 67% of invasive 
pneumococcal cases in 2001 and 74% in 2002.  Data on associated medical conditions was 
unavailable for 7% (7 cases) in 2001 and 3% (3 cases) in 2002.  Cigarette smoking was the most 
prevalent risk factor observed in adults in both years followed closely by alcohol abuse. 
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Table 11:  Associated Medical Conditions Identified in Invasive Pneumococcal Cases – 
Alaska, 2001-2002* 
Medical Condition 





Diabetes 6 (9) 6 (10) 
Cigarette smoking 26 (37) 30 (48) 
Chronic lung disease 18 (26) 19 (31) 
Alcohol abuse 24 (34) 29 (47) 
Immunosuppressive treatment 4 (6) 3 (5) 
Injection drug use 5 (7) 0 (0) 
Asplenia 0 (0) 2 (3) 




Susceptibility testing was performed on 91 isolates in 2001 and 76 isolates in 2002.  Results of 
the testing are presented in the following two tables. 
 
Table 12:  Antibiotic Resistance in Invasive Streptococcus pneumoniae Isolates – Alaska, 2001 
Antibiotic Susceptible Intermediate Resistant I + R Total Tested 
Penicillin 79 (87%) 7 (8%) 5 (5%) 12 (13%) 91 
TMP-sulfa 72 (79%) 2 (2%) 17 (19%) 19 (21%) 91 
Erythromycin 79 (87%) 0 12 (13%) 12 (13%) 91 
Ceftriaxone 85 (93%) 6 (7%) 0 6 (7%) 91 
Tetracycline 89 (98%) 0 2 (2%) 2 (2%) 91 
Chloramphenicol 91 (100%) 0 0 0 91 
Rifampin 91 (100%) 0 0 0 91 
Vancomycin 91 (100%) 0 0 0 91 
Levoflox 91 (100%) 0 0 0 91 
Clindamycin 83 (100%) 0 0 0 83 
 
Table 13:  Antibiotic Resistance in Invasive Streptococcus pneumoniae Isolates – Alaska, 2002 
Antibiotic Susceptible Intermediate Resistant I + R Total Tested 
Penicillin 67 (88%) 7 (9%) 2 (3%) 9 (12%) 76 
TMP-sulfa 61 (80%) 2 (3%) 13 (17%) 15 (20%) 76 
Erythromycin 69 (91%) 0 7 (9%) 7 (9%) 76 
Ceftriaxone 73 (96%) 3 (4%) 0 3 (4%) 76 
Tetracycline 72 (95%) 0 4 (5%) 4 (5%) 76 
Chloramphenicol 74 (97%) 0 2 (3%) 2 (3%) 76 
Rifampin 76 (100%) 0 0 0 76 
Vancomycin 76 (100%) 0 0 0 76 
Levoflox 48 (100%) 0 0 0 48 
Clindamycin 74 (97%) 0 2 (3%) 2 (3%) 76 
 
Cut points from the Minimum Inhibitory Concentration (MIC) Interpretive Standards were used 
to determine if an isolate was ‘susceptible’, ‘intermediate’, or ‘resistant’ to the antibiotic being 
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tested (National Committee for Clinical Laboratory Standards (NCCLS) MIC Testing, 
Supplemental Tables, M100-S10 (M7), January, 2000).  The MIC Interpretive Standards 
definitions of ‘susceptible’, ‘intermediate’, and ‘resistant’ can be found in the Appendix. 
 
Serotypes found in the PCV7 vaccine are more likely to be non-susceptible to penicillin and 
erythromycin than non-vaccine serotypes.  One potential benefit of the vaccine is an anticipated 
decline in antibiotic resistance among circulating pneumococci.  The data in the following graph 
supports this assumption; since the initiation of the PCV7 vaccine in 2001, antibiotic resistance 
has dropped.  TMP-sulfa resistance has declined from 32.1% of isolates tested in 2000 to 20% in 
2002, erythromycin resistance from 20.8% in 2000 to 9% in 2002, and penicillin fully resistant 
isolates from 13.2% in 2000 to 3% in 2002. 
 
Figure 9:  Trends in Antibiotic Resistance Among 






























       *Pen-FR = fully resistant, Pen-NS = non-susceptible 
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In 2001, there were 10 cases of invasive Haemophilus influenzae in Alaska, giving a statewide 
rate of 1.6/100,000 persons per year.  This rate was slightly higher than the national projected 
rate of 1.3/100,000 persons per year, as stated in the Active Bacterial Core Surveillance (ABCs) 
Report Emerging Infections Program Network, 2001.  In 2001, two Haemophilus influenzae 
cases resulted in death, giving a case-fatality ratio of 20%.   
 
In 2002, there were 11 cases of invasive Haemophilus influenzae in Alaska, for a statewide rate 
of 1.7/100,000 persons per year.  This rate was higher than the national projected rate of 
1.3/100,000 persons per year, according to the Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network, 2002.  One of these cases resulted in death, giving a 




Figure 10:  Haemophilus influenzae  Disease by Month 








































































The Anchorage area had the highest numbers of reported cases and percentages of reported cases 
both years.  The Anchorage area had 70% (7 cases) and 82% (9 cases) in 2001 and 2002, 
respectively.  The Yukon-Kuskokwim Delta area presented only one case both years and had the 
highest disease rate of just over 4.1/100,000 persons per year in both years.  The Southeast 
region had two cases in 2001 and the Interior had one case in 2002. 
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Figure 11:  Invasive Haemophilus Influenzae , 

























































































Table 14:  Invasive Haemophilus influenzae Cases by Race – Alaska, 2001-2002 
 Race 
Cases      
n (%) 
Age Adjusted 
Rate * % Male 
Deaths  
n (%) 
2001 Alaska Native 3  (30) 2.4 66.7 0 (0) 
 Non-Native† 7  (70) 1.4 83.3 2 (29) 
 Total 10  70 2 (20) 
2002 Alaska Native 6  (55) 4.6 33.3 0 (0) 
 Non-Native 5  (45) 1.0 60 1 (20) 
 Total 11  45.5 1 (9) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
†Includes 1 case for which race was unknown 
 
In 2001, 60% of the cases occurred in non-Natives and 46% in 2002.  Age-adjusted rates were 
calculated for Alaska Natives and non-Natives.  The age-adjusted rate ratio of H. influenzae 
disease for the Alaska Native population compared with the non-Native population in 2001 was 




Haemophilus influenzae cases ranged in age from infancy to 78 years of age in 2001 (median 
41.5 years) and from infancy to 73 years of age in 2002 (median 39.2 years).  Overall, the 
highest rates of disease occurred in children less than 2 years old and in adults greater than 65 
years old during both 2001 and 2002. 
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Figure 12:  Invasive Haemophilus Influenzae  by 
























Figure 13:  Invasive Haemophilus influenzae , Cases & 




















































Rates of disease in Alaska Native versus non-Native populations by age group were variable 
between the years 2001 and 2002; overall numbers of cases and rates by race and age group for 
the two year reporting period are presented in Figure 13.  In 2001, the highest rates of disease 
occurred in Alaska Natives 2 to 4 years of age (12.8/100,000 persons per year) and those greater 
than 65 years old (15/100,000 persons per year).  There were no cases of Haemophilus 
influenzae in the 2-4 year old age group in non-Natives and the rate of disease in those greater 
than 65 was less than half that of the Alaska Native population in that category.  No H. 
influenzae cases were reported in Alaska Natives less than two years old in 2001, however, in 
2002, the rate of disease in this age category increased to 56/100,000 persons per year compared 




Primary clinical presentations were determined by a review of the discharge diagnoses from each 
patient’s individual medical record associated with the illness resulting in the culture.  For cases 
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with more than one diagnosis, the most serious Haemophilus influenzae-related diagnosis was 
recorded as the primary clinical presentation.  
 
In 2001, all isolates of Haemophilus influenzae were from blood samples.  In 2002, eight isolates 
were from blood samples, two were from CSF, and one from peritoneal fluid.  
 
Table 15:  Primary Clinical Presentation of Invasive Haemophilus influenzae - Alaska, 
2001-2002 
Primary Presentation 
2001 Cases 2002 Cases 
n (%) n (%) 
Pneumonia 5 (50) 4 (36.4) 
Septicemia 4 (40) 3 (27.3) 
Meningitis 0 (0) 2 (18.2) 
Empyema 1 (10) 0 (0) 
Peritonitis 0 (0) 1 (9.1) 
Pericarditis 0 (0) 1 (9.1) 




All isolates received at AIP are serotyped.  The bacterial capsule is the basis for serotyping and is 
the primary virulence factor.  Serotype B has been the most common serotype in the past, but its 
prevalence has decreased with use of the childhood Hib vaccine.  Surveillance of serotypes is 
important for monitoring vaccine effectiveness and emergence of non-vaccine serotypes. 
 




AK Native Non-Native Unknown Total AK Native Non-Native Total 
A - - - 0  (0) 2 2 4  (36.4) 
B - 1 - 1  (10) 1 - 1  (9.1) 
D - 2 - 2  (20) - - 0 
F 1 1 1 3  (30) - - 0 
NT 2 2 - 4  (40) 3 3 6  (54.5) 
Total 3 6 1 10 6 5 11 
 
In 2001, the most common serotype was F.  In 2002, serotype A was the most prevalent, 
accounting for 4 (36.4%) of the 11 cases.  Four cases were non-typable in 2001 and 6 were non-




In recent years, the prevalence of Haemophilus influenzae type B has declined due to increased 
use of a childhood vaccine against this serotype.  In 2001, only one case was reported in a 36-
year old non-Native male.   In 2002, only one case occurred in an Alaska Native infant female 
who had received two doses of PedVaxHib, but also had low birth weight and chronic lung 
problems.  The statewide rate for both 2001 and 2002 was 0.16/100,000 persons per year. 
 








Susceptible Intermediate Resistant Susceptible Intermediate Resistant 
Chloramphenicol 9  (90%) 1  (10%) - 11  (100%) - - 
Ceftriaxone 10  (100%) - - 11  (100%) - - 
TMP/sulfa 9  (90%) - 1  (10%) 9  (81.8%) 1  (9.1%) 1  (9.1%) 
 
Susceptibility to ceftriaxone was 100% for both 2001 and 2002.  One isolate demonstrated 
intermediate susceptibility for chloramphenicol and one isolate was resistant to TMP/sulfa in 
2001.  In 2002, all isolates were susceptible for chloramphenicol.  Intermediate susceptibility for 
TMP/sulfa was demonstrated by one isolate; one isolate showed resistance to TMP/sulfa also. 
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F 0.9 Non-Native Anchorage Blood Septicemia F None  








F 5 Unknown Anchorage Blood Septicemia F None  





M 36 Non-Native Other Blood Pneumonia B None  
M 46 Non-Native Other Blood Septicemia NT Alcohol abuse Death 





M 70 Non-Native Anchorage Blood Septicemia D None Death 
M 73 AK Native Other Blood Pneumonia NT None  
M 78 Non-Native Other Blood Pneumonia D None  
*NT = non-typeable 
 












M 2 days AK Native Anchorage Blood Septicemia NT None  
M 0.4 AK Native Other CSF Meningitis A None  
F 0.7 AK Native Other Blood Pneumonia B Chronic lung disease   
M 2 Non-Native Anchorage Blood 
Pericarditis, 
pneumonia 
NT None  
F 24 AK Native Anchorage 
Peritoneal 
Fluid 
Peritonitis NT None  
F 39 AK Native Anchorage CSF Meningitis NT 




F 40 AK Native Other Blood Septicemia A 
Cigarette smoking,  
chronic lung disease 
 
M 59 Non-Native Anchorage Blood Pneumonia A 




M 72 Non-Native Other Blood Pneumonia NT 
Cigarette smoking, 
chronic lung disease 
 
 
F 72 Non-Native Other Blood 
Septicemia, 
cellulitis 
NT Immunosuppressed  
F 73 Non-Native Anchorage Blood Pneumonia A 
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A total of 6 cases of invasive Neisseria meningitidis were reported to AIP in each year of 2001 
and 2002 for an overall rate of invasive N. meningitidis disease in the state of Alaska of 0.9.  The 
Alaska rates are similar to the ABCs 2001 and 2002 national projected rates of 0.7/100,000 and 
0.5/100,000, respectively (Active Bacterial Core Surveillance (ABCs) Report Emerging 
Infections Program Network Neisseria meningitidis, 2001 & 2002).  There were no invasive N. 
meningitidis-related deaths in Alaska in 2001.  In 2002, there was one death which resulted in a 




N. meningitidis cases occurred throughout the year; no clusters of related cases were reported. 
 
Figure 14:  Invasive Neisseria meningitidis , by 





































































In 2001, 83% of invasive N. meningitidis cases in Alaska occurred in the non-Native population 
for an age-adjusted rate of 1.0/100,000 persons per year compared to the Alaska Native rate of 
0.6/100,000 persons per year.  Cases of N. meningitidis were split between the Alaska Native and 
non-Native populations in 2002; there were three in each group.  The age-adjusted rate of disease 
in Alaska Natives was 1.8/100,000 persons per year and the non-Native rate was 0.6/100,000 
persons per year. 
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Rate* % Male 
Deaths 
n (%) 
2001 Alaska Native 1 (17) 0.6 0 0 (0) 
 Non-Native 5 (83) 1.0 40 0 (0) 
 Total 6  33 0 (0) 
2002 Alaska Native 3 (50) 1.8 0 0 (0) 
 Non-Native 3 (50) 0.6 33 1 (33) 
 Total 6  17 1 (17) 




Four of the six invasive N. meningitidis cases in 2001 occurred in Anchorage; the remaining two 
cases were in the Interior and Norton Sound.  In 2002, four of the six cases occurred in 




Invasive N. meningitidis cases reported in 2001 ranged in age from 0.5 to 90 years old; the 
median age was 36.9 years.  Highest rates of disease occurred in children less than two years old 
(5/100,000 persons per year) and children 2-4 years old (3.4/100,000 person per year).  In 2002, 
cases ranged in age from 2.9 years to 52.6 years with a median age of 12.1 years.  Children 2-4 
years old had the highest rates of disease, 6.5/100,000 persons per year. 
 
Figure 15:  Invasive Neisseria meningitidis  by Age 



























Rates of disease in Alaska Native versus non-Native populations by age group were variable 
between the years 2001 and 2002.  In 2001, the highest rates of disease occurred in Alaska 
Native children less than 2 years of age (18.7/100,000 persons per year).  There were no cases of 
invasive Neisseria meningitidis in children less than 2 years old in non-Natives.  No N. 
meningitidis cases were reported in Alaska Natives 2 - 4 years old in 2001, however, in 2002, the 
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rate of disease in this age category increased to 12.5/100,000 persons per year compared to a rate 
of 4.4/100,000 persons per in non-Native children 2 – 4 years old. 
 
Figure 16:  Invasive Neisseria meningitidis , Cases 




















































The primary clinical presentation was determined by a review of the discharge diagnoses 
indicated in each patient’s individual medical record associated with the illness resulting in the 
culture.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the N. 
meningitidis infection was recorded as the primary clinical presentation.  See Table 21 for the 
primary clinical presentations of invasive N. meningitidis in Alaska in 2001 and 2002. 
 
N. meningitidis was isolated from blood samples in 4 of 6 (67%) cases in 2001.  The remaining 2 
cases in 2001 were isolated from cerebrospinal fluid and another unspecified sterile site.  In 
2002, 3 cases (50%) had N. meningitidis isolated from blood and three from cerebrospinal fluid. 
 







Meningitis 2 (33) 5 (83) 
Septicemia 3 (50) 1 (17) 
Pneumonia 1 (17) 0 (0) 




There were no N. meningitidis-related deaths reported in Alaska in 2001.  In 2002, one patient 
died due to infection with Neisseria meningitidis resulting in a case-fatality ratio of 17% for the 
year (1 death out of 6 cases). 
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F 0.6 AK Native Other Blood Septicemia None 
F 4.0 Non-Native Anchorage CSF Meningitis None 
M 24.4 Non-Native Anchorage Other Meningitis Unknown 
F 49.3 Non-Native Anchorage Blood Septicemia None 
M 60.9 Non-Native Other Blood Septicemia Asplenia 
F 90.0 Non-Native Anchorage Blood Pneumonia None 
 













F 2.9 Native Anchorage Blood Meningitis None - 
M 4.3 Non-Native Anchorage CSF Meningitis None - 
F 7.0 Native Other Blood Septicemia None - 
F 17.3 Native Other CSF Meningitis None - 
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A total of 29 cases of invasive Group A Streptococcus (GAS) were reported to AIP in 2001 and a 
total of 41 cases were reported in 2002.  Overall rates of invasive GAS disease in the state of 
Alaska were 4.6/100,000 persons per year in 2001 and 6.4/100,000 persons per year in 2002.  
The Alaska rates are higher than the ABCs 2001 and 2002 national projected rates of 
3.7/100,000 and 3.2/100,000, respectively (Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network group A streptococcus, 2001 & 2002).  In 2001, there 





Cases of Group A Streptococcus occurred throughout the year in 2001 and 2002.  No apparent 
trends in seasonality appear in either year. 
 
Figure 17:  Invasive Group A Streptococcus , by 







































































In 2001, 41% of invasive GAS cases in Alaska occurred in the Alaska Native population for an 
age-adjusted rate of 10.5/100,000 persons per year which was higher than the non-Native rate of 
3.2/100,000 persons per year.  Age-adjusted rates of invasive GAS increased in both the Alaska 
Native and non-Native populations in 2002 to 14.3/100,000 persons per year and 4/100,000 
persons per year, respectively. 
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Rate* % Male 
Deaths 
n (%) 
2001 Alaska Native 12 (41) 10.5 58 2 (17) 
 Non-Native 17† (59) 3.2 63 1 (6) 
 Total 29  62 3 (10) 
2002 Alaska Native 19 (46) 14.3 58 2 (11) 
 Non-Native 22† (54) 4 33 3 (14) 
 Total 41  46 5 (12) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 




Nineteen (66%) of the 29 invasive Group A Streptococcus cases in 2001 were reported in 
Anchorage, 7 cases in the Interior and one case each in Bristol Bay, the Southeast and YK Delta.  
In 2002, 68% (28 cases) occurred in Anchorage, 5 in the Interior, 4 in YK Delta, 2 in the 




Invasive Group A Streptococcus cases reported in 2001 ranged in age from 0.1 to 83.4 years old; 
the median age was 46.5 years.  Highest rates of disease occurred in children less than two years 
old (14.9/100,000 persons per year) and in the 55 - 64 year old age category (12.6/100,000 
person per year).  In 2002, cases ranged in age from 0.1 years to 82.3 years with a median age of 
41 years.  The highest rates of disease occurred in the 65 and older age category, 18.1/100,000 
persons per year. 
 
Figure 18:  Invasive Group A Streptococcus  by 
























Rates of invasive Group A Streptococcus disease in Alaska Natives were higher in the majority 
of age categories in 2001 and 2002 versus non-Native populations.  In 2001, the highest rates of 
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disease occurred in Alaska Natives 55 – 64 years old (43.1/100,000 persons per year) and Alaska 
Native children less than 2 years of age (37.5/100,000 persons per year).  The highest Group A 
Strep disease rate in the non-Native population occurred in the 65 and older age category 
(9.9/100,000 persons per year).  In 2002, the highest rates of disease occurred in Alaska Native 
children 2 – 4 years old (50/100,000 persons per year) and less than two years old (37.3/100,000 
persons per year).  No cases were reported in the non-Native population in either of these age 
categories. 
 
Figure 17:  Invasive Group A Streptococcus , Cases & 























































The primary clinical presentation was determined by a review of the discharge diagnoses 
indicated in each patient’s individual medical record associated with the illness resulting in the 
culture.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the 
GAS infection was recorded as the primary clinical presentation.  Table 25 shows the primary 
clinical presentations of invasive Group A Streptococcus in Alaska for 2001 and 2002. 
 
Group A Streptococcus was isolated from blood samples in all 2001 cases.  In 2002, GAS was 
isolated from blood in 35 (85%) of 41 cases; the remaining cases were isolated from abscesses (3 
cases), wound samples (2 cases) and one unspecified sterile site.  
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Table 25:  Primary Clinical Presentations of Invasive Group A Streptococcus – Alaska, 






Septicemia 11 (38) 6 (15) 
Cellulitis 8 (28) 18 (44) 
Pneumonia 4 (14) 4 (10) 
Empyema 2 (7) 1 (2) 
Bacteremia 0 (0) 2 (5) 
Meningitis 1 (3) 1 (2) 
Epiglottitis 1 (3) 0 (0) 
Peritonitis 0 (0) 1 (2) 
Septic arthritis 0 (0) 1 (2) 
Osteomyelitis 0 (0) 1 (2) 
Necrotizing fasciitis 1 (3) 6 (15) 
Other 1 (3) 0 (0) 
Total 29 41 
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M 0.1 AK Native Other Blood Pneumonia Chronic lung disease  
M 0.7 Non-Native Other Blood Septicemia None  
F 1.6 AK Native Anchorage Blood Septicemia None  













F 29.4 Non-Native Anchorage Blood Septicemia 
Cigarette smoking, alcohol 
abuse, injection drug use 
 
M 32.1 Non-Native Anchorage Blood Septicemia Unknown  
F 35.5 AK Native Anchorage Blood Cellulitis None  
M 37.8 AK Native Anchorage Blood Cellulitis Alcohol abuse  
M 37.8 AK Native Other Blood Septicemia 
Cigarette smoking, alcohol 
abuse 
 
M 38.6 Non-Native Anchorage Blood Septicemia 
Cigarette smoking, alcohol 
abuse 
 
M 42.4 AK Native Anchorage Blood Cellulitis 
Cigarette smoking, chronic 
lung disease, alcohol abuse 
 
M 43 Non-Native Anchorage Blood Pneumonia Cigarette smoking, chronic 
lung disease, alcohol abuse 
 
M 46.5 AK Native Anchorage Blood Cellulitis 
Cigarette smoking, alcohol 
abuse 
 
M 51.5 Non-Native Other Blood 
Necrotizing 
fasciitis, cellulitis 
Cigarette smoking  
F 52 Non-Native Other Blood Cellulitis Diabetes  
F 53.9 Non-Native Anchorage Blood Septicemia 
Cigarette smoking, chronic 
lung disease, diabetes 
Death 
F 54.5 Non-Native Anchorage Blood Septicemia None  
F 55.6 AK Native Other Blood Cellulitis Alcohol abuse  
M 56.5 Non-Native Other Blood Cellulitis 
Cigarette smoking, alcohol 
abuse 
 
M 58.8 AK Native Other Blood Other Alcohol abuse Death 
M 60.5 Unknown Other Blood Septicemia Diabetes  




Chronic lung disease, 
diabetes 
 
M 63.2 AK Native Anchorage Blood Septicemia Diabetes Death 
F 65.9 AK Native Anchorage Blood Septicemia None  
M 66.6 Non-Native Anchorage Blood Cellulitis Diabetes  
F 80 Non-Native Anchorage Blood Pneumonia Chronic lung disease  
M 83.4 Non-Native Anchorage Blood Epiglottitis 
Cigarette smoking, chronic 
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Presentation(s) Associated Medical Conditions Outcome 
M 0.1 AK Native Anchorage Blood Septicemia None  
F 0.6 AK Native Other Abscess Cellulitis None  
F 2.3 AK Native Other Blood Cellulitis Chronic lung disease  
M 2.5 AK Native Other Blood Meningitis None  
M 3.3 AK Native Other Abscess Cellulitis None  
M 4 AK Native Other Blood Septicemia Chronic lung disease  
F 5.7 Non-Native Anchorage Blood Osteomyelitis None  
F 12.4 AK Native Anchorage Blood Cellulitis None  
M 15.9 AK Native Other Abscess Cellulitis None  
M 17.7 AK Native Anchorage Blood Septicemia None Death 
F 18.9 AK Native Anchorage Blood Cellulitis Chronic lung disease  
F 21.5 Non-Native Anchorage Blood Necrotizing fasciitis Cigarette smoking  
F 21.5 Non-Native Anchorage Blood Cellulitis, other Cigarette smoking  
M 24.3 AK Native Other Blood Cellulitis None  
F 25.2 Non-Native Anchorage Blood Septicemia None  
M 25.2 AK Native Anchorage Blood Bacteremia None  
F 25.5 Non-Native Anchorage Wound 
Necrotizing fasciitis, 
cellulitis 
Cigarette smoking  
F 32.1 AK Native Other Blood Septicemia Alcohol abuse  




F 40.7 Non-Native Anchorage Blood Peritonitis, cellulitis Alcohol abuse  




M 43.2 Non-Native Anchorage Other 
Empyema, 
pneumonia, cellulitis 
Cigarette smoking, injection 
drug use 
 
F 44.8 Non-Native Anchorage Blood Cellulitis None  
M 45 Non-Native Anchorage Blood Cellulitis Cigarette smoking  
M 50.1 AK Native Anchorage Blood Cellulitis Alcohol abuse  
M 53 AK Native Anchorage Blood Bacteremia Alcohol abuse, diabetes  
M 53.7 AK Native Anchorage Blood Cellulitis Alcohol abuse, diabetes  
F 56.1 AK Native Anchorage Blood Pneumonia, cellulitis 
Cigarette smoking, chronic lung 
disease, alcohol abuse 
 
F 56.5 Non-Native Anchorage Blood Cellulitis Cigarette smoking, chronic lung 
disease 
Death 
F 57.1 Non-Native Other Blood Cellulitis None  
M 60.3 Non-Native Anchorage Blood 
Pneumonia, cellulitis, 
other 
Alcohol abuse  
F 61.6 AK Native Anchorage Blood Pneumonia 




F 61.7 Non-Native Anchorage Blood Necrotizing fasciitis None  
M 64.5 Non-Native Other Blood Cellulitis Chronic lung disease, diabetes  
F 69.6 Non-Native Other Blood Cellulitis None  
F 69.7 AK Native Anchorage Blood Cellulitis None Death 
M 70.1 Non-Native Anchorage Blood Necrotizing fasciitis Diabetes Death 
F 72.9 Non-Native Other Blood Cellulitis None  
M 75.6 Non-Native Anchorage Blood Necrotizing fasciitis None  
F 77.9 Non-Native Anchorage Blood Septicemia None Death 
M 82.3 Unknown Other Blood Pneumonia, cellulitis None  
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A total of 20 cases of invasive Group B Streptococcus (GBS) were reported to AIP in 2001 and a 
total of 23 cases were reported in 2002.  Overall rates of invasive GBS disease in the state of 
Alaska were 3.6/100,000 persons per year in 2001 and 2002.  The Alaska rate is lower than the 
ABCs 2001 and 2002 national projected rates of 6.9/100,000 and 7.0/100,000, respectively 
(Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network group 
B streptococcus, 2001 & 2002).  In 2001, there was one GBS-related death and 5 GBS-related 




Cases of Group B Streptococcus occurred throughout the year in 2001 and 2002.  No apparent 
seasonal trends appear in either year. 
 
Figure 20:  Invasive Group B Streptococcus , by 








































































In 2001, 25% of invasive Group B Streptococcus cases in Alaska occurred in the Alaska Native 
population for an age-adjusted rate of 4.4/100,000 persons per year compared with the non-
Native rate of 2.9/100,000 persons per year.  Age-adjusted rates of invasive GBS decreased 
slightly in the Alaska Native population in 2002 (4.2/100,000 persons per year) and increased in 
the non-Native population to 3.4/100,000 persons per year. 
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Rate* % Male 
Deaths 
n (%) 
2001 Alaska Native 5 (25) 4.4 80 0 (0) 
 Non-Native 15 (75) 2.9 60 1 (7) 
 Total 20  65 1 (5) 
2002 Alaska Native 5 (22) 4.2 60 0 (0) 
 Non-Native 18 (78) 3.4 50 5 (28) 
 Total 23  52 5 (22) 




In 2001, 19 of the 20 reported GBS cases occurred in Anchorage; one case was reported in 
Southeast Alaska.  Seventy four percent (17 cases) of invasive GBS reported in 2002 occurred in 




Invasive Group B Streptococcus cases reported in 2001 ranged in age from newborn to 85.6 
years old; the median age was 45 years.  Highest rates of disease occurred in children less than 
two years old (14.9/100,000 persons per year) and in the 65 and older age category (5.4/100,000 
person per year).  In 2002, cases ranged in age from newborn to 75.4 years with a median age of 
46.3 years.  As in 2001, the highest rates of disease occurred in children less than two years old 
and person 65 and older, however, the rates more than doubled in each category to 38.8/100,000 
in the less than two year olds and to 13/100,000 in the 65 and older age group. 
 
Figure 21:  Invasive Group B Streptococcus  by 

























Rates of GBS disease in Alaska Native versus non-Native populations by age group were 
variable between the years 2001 and 2002.  In 2001, the highest rates of disease occurred in non-
Native children less than 2 years of age (20.2/100,000 persons per year).  There were no cases of 
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invasive GBS in children less than 2 years old in Alaska Natives, however, in 2002, the rate of 
disease in this age category increased to 18.7/100,000 persons per year.  Rates of disease in non-
Native children less than two years of age more than doubled in 2002 to 45.8/100,000 persons 
per year.  
 
Figure 22:  Invasive Group B Streptococcus , Cases & 

























































The primary clinical presentation was determined by a review of the discharge diagnoses 
indicated in each patient’s individual medical record associated with the illness resulting in the 
culture.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the 
GBS infection was recorded as the primary clinical presentation.  In 2001, the most common 
clinical presentation was septicemia which occurred in 8 cases (40%).  Two cases of 
osteomyelitis had additional presentations, one with septic arthritis and one with cellulitis.  The 
most common clinical presentation in 2002 was cellulitis (6 cases, 26%); there were no 
additional presentations reported. 
 
Group B Streptococcus was isolated from blood in 18 (90%) of 20 cases in 2001; one case was 
isolated from cerebrospinal fluid and one from joint fluid.  In 2002, 74% (17 of 23 cases) were 
isolated from blood, 3 cases from cerebrospinal fluid, 2 cases from autopsy samples and one case 
from an unspecified sterile site. 
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Table 29:  Primary Clinical Presentations of Invasive Group B Streptococcus – Alaska, 







Septicemia 8 (40) 5 (22) 
Cellulitis 3 (15) 6 (26) 
Pneumonia 4 (20) 3 (13) 
Meningitis 1 (5) 5 (22) 
Amnionitis 1 (5) 0 (0) 
Peritonitis 1 (5) 2 (9) 
Endocarditis 0 (0) 1 (4) 
Osteomyelitis 2 (10) 0 (0) 
Other 0 (0) 1 (4) 
Total 20 23 
 
Surveillance of Invasive Bacterial Disease in Alaska, 2001-2002                                          37 












M 1 day Non-Native Anchorage Blood Septicemia None Death 
M 1 day Non-Native Anchorage Blood Septicemia None  
F 0.03 Non-Native Anchorage CSF Meningitis None  
M 18.8 AK Native Anchorage Joint fluid Cellulitis Alcohol abuse  
F 23.9 Non-Native Anchorage Blood Pneumonia None  




F 36.9 Non-Native Anchorage Blood Amnionitis None  
M 42.3 Non-Native Anchorage Blood Cellulitis Alcohol abuse  
M 44.1 Non-Native Anchorage Blood Septicemia 
Cigarette smoking, 
chronic lung disease, 
alcohol abuse 
 
F 44.6 Non-Native Anchorage Blood Cellulitis None  












M 49.5 Non-Native Anchorage Blood Peritonitis Cigarette smoking, 
alcohol abuse 
 
F 51 Non-Native Anchorage Blood Septicemia Diabetes  
F 53.6 Non-Native Anchorage Blood Septicemia Cigarette smoking  
M 56.1 AK Native Anchorage Blood Pneumonia 
Cigarette smoking, 
alcohol abuse, diabetes 
 




M 76.8 AK Native Other Blood Septicemia Diabetes  
M 85.6 Non-Native Anchorage Blood Pneumonia Cigarette smoking  
 
 
Surveillance of Invasive Bacterial Disease in Alaska, 2001-2002                                          38 












F 1 day Non-Native Anchorage Blood Septicemia None  
F 1 day Non-Native Anchorage Blood Pneumonia None  
F 0.01 Non-Native Anchorage CSF Meningitis None  
F 0.01 Non-Native Anchorage CSF Meningitis None  
M 0.1 Non-Native Anchorage CSF Meningitis None  
F 0.2 Non-Native Anchorage Autopsy Other Unknown Death 
F 0.2 AK Native Other Blood Meningitis None  
F 0.3 Non-Native Other Autopsy Pneumonia None Death 
F 28 Non-Native Anchorage Blood Cellulitis Diabetes  
M 39.8 Non-Native Other Blood Peritonitis 
Cigarette smoking, 
alcohol abuse, diabetes 
 
M 42.9 Non-Native Anchorage Blood Septicemia 
Cigarette smoking, 
alcohol abuse, diabetes 
 
M 46.3 AK Native Other Blood Endocarditis Diabetes  
M 46.7 AK Native Anchorage 
Peritoneal 
fluid 
Peritonitis Alcohol abuse  
M 49 Non-Native Anchorage Blood Septicemia Cigarette smoking Death 
F 49.8 AK Native Anchorage Blood Cellulitis Diabetes  
M 51.5 Non-Native Other Blood Cellulitis Diabetes  
M 55.8 Non-Native Anchorage Blood Meningitis Alcohol abuse Death 
F 63.1 Non-Native Other Blood Cellulitis Diabetes  
M 65.9 AK Native Anchorage Blood Cellulitis Diabetes  
F 70.1 Non-Native Anchorage Blood Cellulitis None  
M 72.9 Non-Native Anchorage Blood Pneumonia 
Chronic lung disease, 
diabetes 
Death 
M 74 Non-Native Anchorage Blood Septicemia Diabetes  
M 75.4 Non-Native Anchorage Blood Septicemia Chronic lung disease  
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Appendix 
 
MIC Interpretive Standards Definitions:  
 
 NCCLS provides recommended interpretive categories for various Minimum Inhibitory Concentration 
values (cut points) for each organism which are defined as follows:* 
 
 1.  Susceptible (S):   
 
The “susceptible” category implies that an infection due to the strain may be appropriately treated 
with the dosage of antimicrobial agent recommended for that type of infection and infecting 
species, unless otherwise contraindicated. 
 
2.  Intermediate (I):   
 
The “intermediate” category includes isolates with antimicrobial agent MICs that approach 
usually attainable blood and tissue levels and for which response rates may be lower than for 
susceptible isolates.  The “intermediate” category implies clinical applicability in body sites 
where the drugs are physiologically concentrated (e.g., quinolones and β-lactams in urine) or 
when a high dosage of a drug can be used (e.g., β-lactams).  The “intermediate” category also 
includes a buffer zone which should prevent small, uncontrolled technical factors from causing 




3.  Resistant (R):   
 
Resistant strains are not inhibited by the usually achievable systemic concentrations of the agent 
with normal dosage schedules and/or fall in the range where specific microbial resistance 




* NCCLS, MIC Testing, Supplemental Tables, M100-S10 (M&), January 2000, p.9.   
 
